BBI 355
Alternative Names: BBI-355Latest Information Update: 13 Nov 2024
Price :
$50 *
At a glance
- Originator Boundless Bio
- Class Antineoplastics; Small molecules
- Mechanism of Action Checkpoint kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 07 Nov 2024 Adverse events data from a phase I/II POTENTIATE trial in Solid tumours released by Boundless Bio
- 08 Apr 2024 Efficacy data from a phase I/II trial in Solid tumors released by Boundless Bio
- 05 Apr 2024 Pharmacodynamics data from a phase I/II POTENTIATE trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research